Shaveta Vinayak, MD, MS | Authors



Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?

June 19, 2019

In this article, we provide a case-based expert opinion on the duration of extended adjuvant endocrine therapy, use of biomarkers in guiding this decision, and toxicities to be considered when recommending this treatment.

mTOR Inhibitors in the Treatment of Breast Cancer

January 15, 2013

Efforts to identify clinical biomarkers of response or resistance to mTOR inhibitors are ongoing. This review will summarize results of preclinical and clinical studies as well as ongoing clinical trials with mTOR or dual PI3K/mTOR inhibitors.